MIF and breast cancer: A clinical trial revealed that the peak MIF plasma concentration is about 10 μM, which is close to the effective concentration we investigated in breast cancer cells in vitro, 1-2 hours and remains in the micromolar range for the next 24-48 hours after a single dose of 200 mg MIF administration in health female volunteers 25.